4-(trimethylsilanyloxy)cyclohexanecarboxylic acid ethyl ester

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 4-(trimethylsilanyloxy)cyclohexanecarboxylic acid ethyl ester
• 英文别名: Ethyl4-((trimethylsilyl)oxy)cyclohexanecarboxylate；ethyl 4-trimethylsilyloxycyclohexane-1-carboxylate
• 化学式: C₁₂H₂₄O₃Si
• 分子量: 244.406
• InChiKey: RSWFWXLMBUHSEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.96
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(trimethylsilanyloxy)cyclohexanecarboxylic acid ethyl ester 在 三氟甲磺酸三甲基硅酯 、 一水合肼 作用下， 以 二氯甲烷 、 正丁醇 为溶剂， 反应 73.0h， 生成 trans-4-(isopropoxy)cyclohexanecarboxylic acid hydrazide
  参考文献：
  名称：

  OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS

  摘要：

  本发明提供了4H，6H-5-氧杂-2,3,10b-三氮杂苯并[e]吲哚的化合物，其化学结构如下所示： 其中R1和R2如本文所定义，并且这些化合物作为V1a受体调节剂，特别是作为V1a受体拮抗剂，其制备方法，含有它们的药物组合物以及它们作为药物的用途。

  公开号：

  US20130079333A1
• 作为产物：
  描述：

  三甲基氯硅烷 、 4-羟基环己烷甲酸乙酯 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.08h， 以85%的产率得到4-(trimethylsilanyloxy)cyclohexanecarboxylic acid ethyl ester
  参考文献：
  名称：

  PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

  摘要：

  这项发明涉及USP7抑制剂，用于治疗癌症、神经退行性疾病、免疫紊乱、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病、细菌感染和疾病，具有以下结构式： 其中m、n、X1、X2、R1-R5、R5'和R6如本文所述。

  公开号：

  US20160185785A1

文献信息

• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] COMPOSÉS TRICYCLIQUES INNOVANTS SERVANT D'INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089797A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，该化合物是野生型异柠檬酸脱氢酶（IDH）抑制剂：(I)。本发明还涉及将此处描述的三环化合物用于潜在治疗或预防涉及一个或多个突变IDH酶的癌症。本发明还涉及包含这些化合物的组合物。本发明还涉及将这些组合物用于潜在预防或治疗此类癌症。
• [EN] OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS<br/>[FR] OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULÈNES EN TANT QU'ANTAGONISTES DE V1A
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013045373A1

  公开（公告）日：2013-04-04

  The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明提供了4H,6H-5-氧杂-2,3,10b-三氮杂苯并[e]吖啶烯，其作为V1a受体调节剂，特别是作为V1a受体拮抗剂，以及它们的制备方法、含有它们的药物组合物和它们作为药物的用途。本发明的活性化合物在经前痛、男性或女性性功能障碍、高血压、慢性心力衰竭、抗利尿素分泌异常、肝硬化、肾病综合征、焦虑、抑郁障碍、强迫症、自闭症谱系障碍、精神分裂症和攻击性行为等情况中作为治疗药物具有作用，既可在外周起作用，也可在中枢起作用。
• ALKYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES
  申请人：Schnider Patrick

  公开号：US20100125066A1

  公开（公告）日：2010-05-20

  The present invention is concerned with alkylcyclohexylethers of dihydro-tetraazabenzoazulenes, i.e. alkylcyclohexylethers of 5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene s of formula I wherein R 1 , R 2 and R 3 are as described herein, their manufacture, and pharmaceutical compositions containing them. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists. The compounds are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

  本发明涉及二氢四氮杂苯并蓝紫啉的烷基环己醚，即式I的5,6-二氢-4H-2,3,5,10b-四氮杂苯并[ e]蓝紫啉的烷基环己醚，其中R1、R2和R3如本文所述，它们的制备以及含有它们的药物组合物。根据本发明的化合物作为V1a受体调节剂，特别是作为V1a受体拮抗剂。这些化合物可用作治疗剂，对外周和中枢在经痛、男性或女性性功能障碍、高血压、慢性心力衰竭、抗利尿素分泌失调、肝硬化、肾病综合症、焦虑、抑郁症、强迫性障碍、自闭症谱系障碍、精神分裂症和攻击性行为等症状中具有用途。
• Addition of Dialkylzinc to Ketones in the Presence of Silylating Agents:  Synthesis of Functionalized Tertiary Silyl Ethers
  作者：Chiara Alvisi、Sonia Casolari、Anna Luisa Costa、Monica Ritiani、Emilio Tagliavini

  DOI：10.1021/jo971639x

  日期：1998.2.1
• PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160185785A1

  公开（公告）日：2016-06-30

  The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X 1 , X 2 , R 1 -R 5 , R 5′ and R 6 are described herein.

  这项发明涉及USP7抑制剂，用于治疗癌症、神经退行性疾病、免疫紊乱、炎症性疾病、心血管疾病、缺血性疾病、病毒感染和疾病、细菌感染和疾病，具有以下结构式： 其中m、n、X1、X2、R1-R5、R5'和R6如本文所述。